The real costs of research funding cuts |

Research at the University of Wisconsin–Madison drives innovation, saves lives, creates jobs, supports small businesses, and fuels the industries that keep America competitive and secure. It makes the U.S.—and Wisconsin—stronger. Federal funding for research is a high-return investment that’s worth fighting for. Learn more about the impact of UW–Madison’s federally funded research and how you can help.

Barbara Smith Ballen began traveling to the University of Wisconsin–Madison campus last year to receive brain scans and blood draws, not as a medical patient but as a research participant. She’s part of an ambitious and potentially transformative study aimed at better understanding Alzheimer’s disease and related dementias. A mother of five in her 70s, Smith Ballen was motivated to make the regular trek to UW–Madison because of her family history with dementia. She witnessed her father’s struggle in the years prior to his death.

Smith Ballen wants to help UW–Madison researchers find effective treatments for dementia and perhaps even a cure — if not for her dad, then for all future patients and families whose lives are forever changed by the diagnosis.

“I am committed to doing whatever I can to help end this devastating disease and hopefully others will follow my lead,” Smith Ballen said when the project began in October 2024. “I truly believe that this research team has what it takes to make a breakthrough; they just need to stay persistent.”

Now, UW–Madison’s ability to continue such research faces uncertainty. That’s due to a new federal policy from the National Institutes of Health (NIH), which is the study’s primary funder and the largest source of biomedical research funding in the United States.

In February, the agency announced a new cap on a form of supplemental funding that supports the infrastructure and workforce necessary to carry out complex research at institutions like UW–Madison. The new cap is much lower than the rate that the university previously negotiated with the NIH, meaning that it stands to lose tens of millions of dollars in annual research support.

But it’s not really the money that’s at stake. It’s what that reliable funding enables: the ability to advance life-saving research and innovation.

The ins and outs of ‘indirects’ funding

The cuts proposed by NIH relate to a funding stream known as indirect costs, or simply “indirects.” They represent supplemental support on top of the funding that NIH sends directly to researchers who have been awarded grants. At UW–Madison and other research institutions, these indirects are crucial to sustaining research on Alzheimer’s, cancer, diabetes and other critical diseases.

Before February, the system for negotiating NIH indirects had been in place for decades, providing institutions like UW–Madison a predictable funding model to plan investments in the buildings, equipment, service contracts and personnel required to carry out cutting-edge biomedical research.

Under that system, each institution negotiated an indirect rate with the NIH every few years. Negotiated rates range considerably among institutions because they depend on variables like the local cost of living, maintenance and service contract fees, and the complexity of the institution’s research portfolio. UW–Madison’s most recent negotiated rate of 55.5% to support research facilities and administration was near the median among institutions nationally. That rate meant the university would receive 55.5 cents of indirect support from the NIH for every dollar of direct grant funding the agency awarded to affiliated researchers. In February, the NIH imposed a cap of 15% for indirect funds across all institutions, which has since been blocked in federal court and continues to be litigated.

The proposed rate cut from 55.5% to 15% would have wide-ranging and potentially devastating consequences for essential research at UW–Madison.